As the prevalence of neurodegenerative diseases rapidly rises, researchers at the ongoing HLTH 2023 conference highlighted how biomarker development is urgently needed for treatment breakthroughs to occur.
In the United States, as many as 6.2 million people may have Alzheimer’s disease, according to a 2022 report from the Alzheimer’s Disease Association and nearly one million Americans are living with Parkinson’s disease.
Despite advances in biomarker research for Alzheimer’s disease, Jamie Eberling, Senior Vice President, Research Resources at the Michael J. Fox Foundation, said progress across the neurodegenerative disease space is limited until biomarkers are identified for all pathologies.
